Biocon Limited · NSE:BIOCON
Biocon — Fact Sheet (September 2017)
5 slides from Biocon's fact sheet, September 2017
Slide 1: Biocon Group Fact Sheet September 2017
BIOCON GROUP FACT SHEET September ‐ 2017
Slide 2: Biocon Limited (Consolidated) Balance Sheet
BIOCON LIMITED (CONSOLIDATED) BALANCE SHEET (Rs Cr) Sep 30, 2017 March 31, 2017 ASSETS Non‐current assets (a) Property, plant and equipment 3,603 3,553 (b) Capital work‐in‐progress 574 533 (c) Investment property 1 1 (d) Goodwill 26 26 (e) Other intangible assets 41 46 (f) Intangible assets under de
Slide 3: Profit & Loss Statement H1 FY18 vs H1 FY17
BIOCON LIMITED (CONSOLIDATED) PROFIT & LOSS STATEMENT (Rs. Crores) H1 H1 Variance Particulars FY 18 FY 17 INCOME Small molecules 713 839 ‐15% Biologics 340 316 7% Branded formulations 306 295 4% Research services 626 578 8% Inter‐segment (83) (81) 3% Revenue from operations # 1,902 1,947 ‐2% Other i
Slide 4: Profit & Loss Statement Q2 FY18 vs Q2 FY17
BIOCON LIMITED (CONSOLIDATED) PROFIT & LOSS STATEMENT (Rs. Crores) Q2 Q2 Variance Particulars FY 18 FY 17 INCOME Small molecules 351 403 ‐13% Biologics 156 156 0% Branded formulations 176 137 29% Research services 335 303 11% Inter‐segment (49) (44) 10% Revenue from operations # 969 955 2% Other inc
Slide 5: Profit & Loss Statement Q2 FY18 vs Q1 FY18
BIOCON LIMITED (CONSOLIDATED) PROFIT & LOSS STATEMENT (Rs. Crores) Q2 Q1 Variance Particulars FY 18 FY 18 IndAS INCOME Small molecules 351 363 ‐3% Biologics 156 184 ‐15% Branded formulations 176 130 35% Research services 335 291 15% Inter‐segment (49) (34) 41% Revenue from operations # 969 934 4% Ot